Subscribe for full access
Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Recommendation Rating
1.67
1
2
3
4
5
1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL
Analysts’ Price Targets
Mean 15.43
Low: 10.91
High: 18.01
Total Analysts: 7
Company Profile
OSE Immunotherapeutics SA, formerly Orphan Synergy Europe Pharma SA, is a France-based company, engaged in clinical stage biotechnological sector. It develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The Company’s research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. It provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.
We do our best to screen stocks as accurately as possible. Please let us know in the Community if you spot an error or find something questionable. Jazaak Allahu khairan.
